Immune checkpoint therapy in liver cancer.

about

Nobel committee honors tumor immunologists Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

P2860

Q58096321-119D0494-C5A0-46FA-8388-AC79F995B1D9 Q59127444-F8C85DC2-C511-4D76-8559-BD31851997EA Q59136123-93F24CF3-3518-4F53-964E-052D871CFFAF

P2860

Immune checkpoint therapy in liver cancer.

Item

http://www.wikidata.org/entity/Q55008806

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immune checkpoint therapy in liver cancer.

@en

Immune checkpoint therapy in liver cancer.

@nl

type

Item

label

Immune checkpoint therapy in liver cancer.

@en

Immune checkpoint therapy in liver cancer.

@nl

prefLabel

Immune checkpoint therapy in liver cancer.

@en

Immune checkpoint therapy in liver cancer.

@nl

P1476

Immune checkpoint therapy in liver cancer.

@en

P2093

Chaoliu Dai

http://www.w3.org/2001/XMLSchema#string

Feng Xu

http://www.w3.org/2001/XMLSchema#string

Tianqiang Jin

http://www.w3.org/2001/XMLSchema#string

Yuwen Zhu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Management of hepatocellular carcinoma: An update

The fundamental role of epigenetic events in cancer

The blockade of immune checkpoints in cancer immunotherapy

Immune checkpoint blockade: a common denominator approach to cancer therapy

Locoregional therapy for cholangiocarcinoma

Epigenetics in cancer

CTLA-4 control over Foxp3+ regulatory T cell function

Epidemiology and risk factors: intrahepatic cholangiocarcinoma.

P2888

s13046-018-0777-4

P304

110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13046-018-0777-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104289308

http://www.w3.org/2001/XMLSchema#string

P698

29843754

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

liver neoplasm

P932

5975687

http://www.w3.org/2001/XMLSchema#string

Immune checkpoint therapy in liver cancer.

about

P2860

P2860

Immune checkpoint therapy in liver cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932